Vidutolimod

Presurgical vidutolimod and nivolumab improved tumor control in 55% of stage III cutaneous melanoma patients, with 88% 2-year recurrence-free survival. Plasmacytoid dendritic cells and myeloid cells were enriched in responders, and gut microbiome analysis showed higher Gram-negative bacteria in patients with greatest tumor shrinkage.

A phase II clinical trial combining vidutolimod (TLR9 agonist) and nivolumab (PD-1 inhibitor) in high-risk stage III melanoma patients pre-surgery showed a 55% response rate, with 88% two-year recurrence-free survival and 94% metastasis-free survival in high responders. Published in Cancer Cell, the study led by Diwakar Davar suggests vidu's ability to enrich tumor-infiltrating plasmacytoid dendritic cells (pDCs) and myeloid cells, enhancing T cell-mediated anti-tumor immunity.

Presurgical vidutolimod and nivolumab treatment improved tumor control in 55% of stage III melanoma patients, with high responders showing enriched plasmacytoid dendritic and myeloid cells. Gut microbiome analysis revealed higher Gram-negative bacteria levels in responders, suggesting unique immunotherapy modulation.

A phase 2 trial combining vidutolimod and nivolumab pre-surgery in stage 3 melanoma patients showed 55% tumor control, with 88% two-year recurrence-free survival and 94% metastasis-free survival in high responders. The study identified unique immune signatures and microbiome effects, suggesting vidutolimod's potential in melanoma and other cancers.

DelveInsight's 'Breast Cancer Pipeline Insight 2024' highlights a robust pipeline with 100+ companies developing 120+ drugs, driven by rising incidence, tech advancements, and increased awareness. Key companies and drugs include Ambrx, CSPC ZhongQi, Merus, and ARX788, DP303c, SHR-A1811, among others. FDA fast-track designations and breakthrough therapy designations for drugs like 9MW2821 and inavolisib underscore significant progress.